Results 111 to 120 of about 1,738 (143)

Expanded CD16⁺CD56⁺Granzyme B⁺ NK like CD8⁺ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia. [PDF]

Sci Rep
Hastak P, Phetsouphanh C, Zhang ZH, Bull RA, Shrestha LB, Klemm V, Louie R, Luciani F, Munier CML, Hoppé AC, Keoshkerian E, Beaton B, Rankin K, Wong A, Trotman J, Kelleher AD, Sasson SC.   +16 more
europepmc   +1 more source

Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]

Ann Hematol
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc   +1 more source

SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. [PDF]

Blood Adv
Dutta RP, Lee HH, Leshchenko VV, Shukla RP, Yan F, Liu Y, Kaniskan HÜ, Qiu X, Jin J, Alinari L, Wang M, Parekh S.   +11 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm
Dybowski S, Thode J, Freier M, Saberi D, Nessler S, Geladaris A, Häusser-Kinzel S, Ringelstein M, Torke S, Weber MS.   +9 more
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study. [PDF]

Ann Hematol
Lv Y, Zhu Y, Yang C, Zhang X, Zhang X, Wei J, Ye X, Xu G, Mao L, Mai W, Yang M, Qian J, Tong H, Jin J, Yu W.   +14 more
europepmc   +1 more source

Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data. [PDF]

Ann Hematol
Maqhuzu PN, Bocuk D, Boelz S, Hosseini SK, Leeb C, Renevey F, Mevius A, Greth K, Christofyllakis K.   +8 more
europepmc   +1 more source

Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors. [PDF]

World J Gastroenterol
Liu WN, Dai MS, Lin F, Lin GM.
europepmc   +1 more source

Mechanisms of resistance to bruton's tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways. [PDF]

Ann Hematol
Dong X, Tang S, Chen M, Chen Q, Wang Y, Shi Y, Deng Y, Chen Y, He Z, Yu L, Wang C.   +10 more
europepmc   +1 more source

Identification of Bruton tyrosine kinase mutations in 12 Chinese patients with X‐linked agammaglobulinaemia by long PCR‐direct sequencing

International Journal of Immunogenetics, 2006
SummaryX‐linked agammaglobulinaemia (XLA) is an immunodeficiency caused by Bruton tyrosine kinase (BTK) gene mutations. The disease is characterized by recurrent bacterial infections and profound hypogammaglobulinemia with marked reduction or lack of mature B‐cells in the peripheral blood.
Lee, TL, Lee, BW, Fok, SFS, Jiang, L, Chen, T, Chan, KW, Lau, YL, Yang, X   +7 more
openaire   +4 more sources